MBG453
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 20 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Novartis
- Tags
- Monoclonal Antibody, TIM-3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1861
- NCT Identifier
- NCT04823624
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.